|
US2021015776A1
|
|
Methods of stabilization of levothyroxine sodium tablets
|
|
US2018169061A1
|
|
Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
|
|
WO2017184584A1
|
|
Stable packaging system for moisture and oxygen sensitive pharmaceutical dosage forms
|
|
US2017312226A1
|
|
Pharmaceutical dosage forms
|
|
WO9631203A1
|
|
Composition and process for prevention and treatment of cutaneous delayed hypersensitivity reactions
|
|
US5672358A
|
|
Controlled release aqueous emulsion
|
|
US5552436A
|
|
Process for treating hemangioma
|
|
US5532270A
|
|
Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions
|
|
US5576346A
|
|
Process for treating uremic pruritus
|
|
US5455049A
|
|
Terfenadine oral powder
|
|
WO9407467A1
|
|
Calcium polycarbophil sprinkle
|
